EN DE
Watch Cannabis Poland S.A. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cannabis Poland S.A. (CBD) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Cannabis Poland S.A. stock PLN 0.11, price PLN 0.18, that is 40.6% below the price, quality 13 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLBLOCM00013

CP Cannabis Poland S.A. logo Thin data Nov 10, 2026

Cannabis Poland S.A.

CBD · WAR
Very expensive, weak quality

Our calculation puts a fair price 41% below what the stock costs today.

Low debt
Mixed Growth (revenue 5y +41.6 %/yr in PLN)
Revenue last quarter 21% below a year ago.
Fair value 0.1064 PLN · Strongly overvalued
Quality 13/100
Negative free cash flow
Trails peers (1/8)
Narrow moat 6/100 · thin data
Thin data
Estimate
Watch Cannabis Poland S.A. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

2.58 PLN 0.1600 PLN Fair Value 0.1064 PLN Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 0.1600 PLN – 2.58 PLN · fair‑value band 0.0798 PLN – 0.1330 PLN · the 0.1790 PLN price screens above the 0.1064 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Cannabis Poland in your weekly email

Every Wednesday you see whether Cannabis Poland is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cannabis Poland S.A. operates in the medical cannabis industry in Poland. It distributes and sells cannabidiol (CBD) oils and herbs, inhalers, and vaporizers, as well as dietary supplements and cosmetics for humans and animals.

Show moreShow less

The company sells its products through HempWish.pl and Vapem.eu online stores.

It also engages in the research and development of CBD-based drugs based on scientific council, as well as in the operation of MMedu.eu, an educational platform that provides industry-specific knowledge packages on medical marijuana.

The company was formerly known as Telehorse S.A. and changed its name to Cannabis Poland S.A. in May 2019. Cannabis Poland S.A. was incorporated in 2012 and is headquartered in Warsaw, Poland.

Stock analysis

Cannabis Poland S.A. (CBD) currently trades at 0.1790 PLN, while our estimate is 0.1064 PLN, 41% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 0.0798 PLN (bear) to 0.1330 PLN (bull), the price of 0.1790 PLN sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 13/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Cannabis Poland S.A. reported revenue of 211K PLN in FY2025 versus 381K PLN in FY2021, a compound −13.7%/yr. Reported net income was −1.9M PLN in FY2025.

Key figures

Market cap 14.4M PLN (≈ $3.7M) Micro · P/S ratio 70.1 · EPS (TTM) −0.0300 PLN · Return on equity −164% · Return on assets (EBIT) −80.8% (5-year average) · Operating margin −3,556% · Revenue (TTM) 206K PLN · Revenue growth (YoY) −20.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 34% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −41%, CBD screens richer than that median.

Fair Value

Bear 0.0798 PLN Fair Value 0.1064 PLN Bull 0.1330 PLN
Price 0.1790 PLN · Downside -40.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 13/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 11
Are margins and returns getting better?
Cashflow 16
Do the profits arrive as real cash?
Financial strength 40
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 31
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−15.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+41.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−25.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,727.3% (2020) → −1,136.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CBD screens overvalued: fair value 41% below the price. Compare with Merck KGaA →

Compare Cannabis Poland S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 13 · Bottom 25%
Fair Value upside −40.6% · Below median
Profitability
Return on assets −64.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −20.5% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 9.47× · Priciest 25%
P/S (12 months) 70.06× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs CBD
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs CBD
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs CBD
Haleon plc HLN $9.06 $8.62 −5% vs CBD
Merck KGaA MRK €149.35 €109.18 −27% vs CBD
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs CBD
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs CBD
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs CBD
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs CBD
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs CBD

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cannabis Poland S.A.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cannabis Poland S.A. Fair Value". https://www.fairvalue-calculator.com/stock/CBD

Frequently asked questions

Is Cannabis Poland S.A. (CBD) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 0.1064 PLN versus a price of 0.1790 PLN, about 41% lower (overvalued).
What is the fair value of CBD?
Our estimate for Cannabis Poland S.A. is 0.1064 PLN (as of Nov 10, 2026), built from audited fundamentals. The current price: 0.1790 PLN.
What is the quality score of CBD?
Cannabis Poland S.A. has a Quality Score of 13/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cannabis Poland S.A. (CBD)?
Our calculated price target is the estimate of 0.1064 PLN (as of Nov 10, 2026). Cautious scenario 0.0798 PLN, optimistic scenario 0.1330 PLN. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cannabis Poland S.A. stock forecast for 2026?
Our estimate puts fair value at 0.1064 PLN, about 41% lower versus a price of 0.1790 PLN (overvalued). Cautious scenario 0.0798 PLN, optimistic scenario 0.1330 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Cannabis Poland S.A. (CBD)?
Cannabis Poland S.A. reported trailing-twelve-month revenue of about 206K PLN (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Cannabis Poland S.A. (CBD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cannabis Poland S.A. it is 0.1064 PLN per share (as of Nov 10, 2026), against a price of 0.1790 PLN.
Is Cannabis Poland S.A. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CBD trades above its calculated fair value: price 0.1790 PLN, fair value 0.1064 PLN, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CBD?
No. The price is what the market pays today (0.1790 PLN); the fair value is what the company's own numbers justify (0.1064 PLN). For Cannabis Poland S.A. the two are 0.0726 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Cannabis Poland S.A. worth?
The market values Cannabis Poland S.A. at about 14.4M PLN (market capitalisation, as of Nov 10, 2026). Per share that is 0.1790 PLN; our models calculate a fair value of 0.1064 PLN per share.
What do the bullish and bearish scenarios say about CBD?
Our models span a range for Cannabis Poland S.A.: cautious scenario 0.0798 PLN, base 0.1064 PLN, optimistic 0.1330 PLN per share (as of Nov 10, 2026, price 0.1790 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cannabis Poland S.A. (CBD)?
Balance-sheet figures for Cannabis Poland S.A. (as of Nov 10, 2026): return on equity −163.8%. They feed the Quality Score of 13/100, which measures business quality independently of the share price.
How far is CBD from its 52-week high?
Cannabis Poland S.A. trades at 0.1790 PLN, about 34% below its 52-week high of 0.2700 PLN and 12% above the low of 0.1600 PLN (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1064 PLN is for.
Which stocks are comparable to Cannabis Poland S.A.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cannabis Poland S.A. stock attractive at the current price?
The data as of Nov 10, 2026: price 0.1790 PLN, calculated fair value 0.1064 PLN (−41%), Quality Score 13/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Cannabis Poland S.A. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cannabis Poland S.A. (CBD)?
The closing price on Nov 10, 2026 was 0.1790 PLN. Our estimate is 0.1064 PLN, about 41% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cannabis Poland S.A. right now?
The price sits above even our optimistic bull case (0.1330 PLN). The favourable scenario is already priced in. Weak quality (13/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Cannabis Poland S.A.

How large is the market capitalisation of Cannabis Poland S.A. (CBD)?
The market capitalisation of Cannabis Poland S.A. is 14.4M PLN (≈ $3.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cannabis Poland S.A. (CBD)?
The price-to-sales ratio of Cannabis Poland S.A. is 70.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cannabis Poland S.A. (CBD)?
Earnings per share at Cannabis Poland S.A. are −0.0300 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cannabis Poland S.A. (CBD)?
The return on equity (ROE) of Cannabis Poland S.A. is −164% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cannabis Poland S.A. (CBD)?
On an EBIT basis the return on assets of Cannabis Poland S.A. is −80.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cannabis Poland S.A. (CBD)?
The operating margin of Cannabis Poland S.A. is −3,556% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cannabis Poland S.A. (CBD)?
Revenue at Cannabis Poland S.A. is growing −20.5% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cannabis Poland S.A. (CBD) generate?
The free cash flow of Cannabis Poland S.A. is −2.6M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Cannabis Poland S.A. in the live analysis

One click puts Cannabis Poland S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.